Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
WATERLAND trial
2023-509879-16-00Phase 4Completed
- Sponsor
- Hospital General Universitario de Alicante
- Start
- Jun 2023
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 4, randomised, open-label trial of Ringer-Lactat Fresenius Kabi in acute pancreatitis (AP) (2 arms), sponsored by Hospital General Universitario de Alicante. Primary endpoint: Development of moderately severe to severe acute pancreatitis. Started Jun 2023; status: completed.
02
Drugs
Ringer-Lactat Fresenius Kabi
03
Conditions
acute pancreatitis (AP)
Beyond the preview
Go deeper on 2023-509879-16-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509879-16-00.